An antigenic HIV-1 peptide sequence engineered into the surface structure of transferrin does not elicit an antibody response  by Ali, Stuart A et al.
An antigenic HIV-1 peptide sequence engineered into the surface
structure of transferrin does not elicit an antibody response
Stuart A. Ali1, Heidi C. Joao, Franz Hammerschmid, Jo«rg Eder2, Alexander Steinkasserer3;*
Novartis Research Institute, Brunnerstrasse 59, A-1230 Vienna, Austria
Received 12 July 1999
Abstract One novel approach for the biological delivery of
peptide drugs is to incorporate the sequence of the peptide into
the structure of a natural transport protein such as human serum
transferrin (HST). However, a potential drawback is that the
HST may increase the immunoreactivity of the peptide, in the
same way that carrier proteins can be used to generate highly
immunogenic peptide hapten conjugates. In this study we have
generated a recombinant HST carrier protein that contains a
peptide substrate of HIV-1 protease (VSQNYPIVL). The
protein retained native HST function, and the peptide was
surface exposed since it was immunoreactive in native dot blots,
and was cleaved by HIV-1 protease. Immunisation of rabbits
with the recombinant protein elicited only a very poor anti-
peptide immune response. In contrast, strong anti-peptide
immune responses were raised against both the peptide alone,
and a chemical conjugate of the peptide with HST. These data
demonstrate that it is possible to attenuate the immune response
normally directed against an immunogenic peptide sequence by
engineering into a surface exposed loop of HST. These findings
may have an important impact on the future design of peptide
delivery systems.
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1. Introduction
Human serum transferrin (HST) is a monomeric glycopro-
tein with a molecular mass of around 80 kDa, and is able to
bind tightly, but reversibly, two ferric irons together with two
bicarbonate co-ions. It has two roles. First, it mediates the
transport and uptake of iron into cells. Second, it regulates
the availability of free iron in the body £uids, preventing the
production of potentially toxic free radicals and providing
bacteriostatic functions.
In recent years, several studies have demonstrated that the
transferrin uptake pathway is useful for delivering drugs into
transformed and activated cells. These cells express high levels
of transferrin receptors because they have a high requirement
for iron. Particularly, Laske and co-workers showed that
HST/diphtheria toxin conjugates are e¡ective at eradicating
human glioma tumors in mice [1]. Treatment produced on
average of 95% regression in tumour volume after 30 days.
In contrast, tumour volumes in animals treated with free toxin
increased by about 300%, and by 1000% in the controls. A
clinical trial has demonstrated that this conjugate is also ef-
fective in humans [2]. Patients with recurrent malignant brain
tumours received the conjugate intra-cerebrally using high-
£ow interstitial microinfusion. Two of the 15 treated patients
showed complete remission, and nine showed a 50% reduction
in tumour volume, as determined by nuclear magnetic reso-
nance imaging. In none of the patients were there any signs of
systemic toxicity. These results clearly demonstrate that this is
an e¡ective approach for drug delivery.
Recently, we proposed an alternative, novel way to use the
transferrin uptake pathway for the cellular delivery of thera-
peutic peptide drugs [3]. Instead of using chemical conjugation
to join the peptide drug to transferrin, we reasoned that it
should be possible to incorporate the drug into the structure
of transferrin using recombinant protein engineering. The
short biological half-life of peptide drugs is often a major
problem and those which are water-soluble usually do not
penetrate the cell wall readily. A recombinant transferrin ana-
logue, containing the therapeutic peptide within the structure
would bypass these problems.
Surface exposed loops of globular proteins can frequently
tolerate insertions of additional amino acids without altering
the function of the protein [4]. Therefore, it should be possible
to introduce peptide sequences into the surface of transferrin
without destroying function. As such, the peptides would
‘hide’ in the surface of the transferrin analogue, be actively
uptaken into the cell, and then recognised (i.e. be functional)
at the site of inhibitory activity. In this scenario, the function
of the transferrin molecule would be analogous to that of a
‘Trojan Horse’ for the delivery of the peptide sequence into
the cell. To demonstrate proof of principle, we generated
functional transferrin analogues targeted to the protease of
HIV-1; the etiological agent of AIDS. In this study, a peptide
substrate (VSQNYPIVL) of HIV-1 protease was introduced
into a surface exposed loop of HST. The HST analogue re-
tained native transferrin function and could be cleaved by
HIV-1 protease [3].
Although our study demonstrated that HST could be used
for the biological delivery of a peptide [3], we did recognise
one potential drawback; it is possible that the HST could
enhance the immunogenicity of the peptide, in the same way
that carrier proteins can be used to generate highly immuno-
genic peptide hapten conjugates. In the present study we chose
to examine the immunogenicity of the HST analogue. Immu-
nisation of rabbits with the recombinant protein elicited only
a very poor anti-peptide immune response. In contrast, strong
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anti-peptide immune responses were raised against both the
peptide alone, and a chemical conjugate of the peptide with
HST. These data demonstrate that it is possible to attenuate
the immune response normally directed against an immuno-
genic peptide sequence by engineering into a surface exposed
loop of HST. These ¢ndings may have an important impact
on the future design of peptide delivery systems.
2. Materials and methods
2.1. Reagents
Native HST was obtained from Sigma (Vienna, Austria) and Boeh-
ringer Mannheim (Vienna, Austria). Peptides were provided by
Genosys (Cambridge, UK), who also synthesised the HST/HIV-1 pro-
tease cleavage site peptide conjugate. Antisera were produced in rab-
bits using standard techniques.
2.2. Recombinant proteins
Production of the recombinant proteins used in this study has been
described in an earlier paper [3]. Essentially, molecular modelling was
used to identify an insertion site (amino acid 289 in the transferrin
sequence) which was located in a surface exposed loop of the protein,
and which was distant from biologically active domains. A nucleotide
insertion coding for the HIV-1 protease cleavage site VSQNYPIVL
was then cloned into this site using recombinant PCR. This generated
a mutant, termed HST M289. These proteins were then expressed to
high levels using a baculovirus expression vector system, and puri¢ed
from cell supernatants to homogeneity using column chromatography.
We demonstrated (i) that the proteins retained native HST function,
(ii) that the peptide cleavage site engineered into M289 was surface
located as predicted, and (iii) that inserted peptide sequence in M289
was cleaved by HIV-1 protease.
2.3. Analysis of immunogenicity of protease cleavage site in M289
Rabbits were immunised using standard procedures three times at
monthly intervals with the M289 analogue, a conjugate of HST and
the HIV-1 protease cleavage site peptide, or the peptide alone. After
4 months, rabbit serum was collected, and titres of antibodies speci¢c
for the HIV-1 protease cleavage site or HST assayed using an anti-
body capture ELISA.
An antibody capture ELISA was established according to standard
methods. The wells of an ELISA plate (Maxisorb, Nunc) were coated
with the peptide (20 ng/well) or HST (40 ng/well) for 3 h at room
temperature, non-speci¢c binding sites on the plate blocked with ei-
ther 0.1% (v/v) Tween-20 in PBS (PBS-T) or 3% (w/v) bovine serum
albumin in PBS overnight at 4‡C. After extensive washing in PBS-T,
serum samples (100 Wl) were applied to the ELISA plate wells, and
incubated for 1 h at 37‡C to allow antigen capture. For detection,
wells were treated ¢rst with a biotinylated primary detection antibody
(100 Wl biotinylated rabbit anti-HST polyclonal, diluted 1:5000 in
PBS-T) and then with a streptavidin-horse radish peroxidase (HRP)
conjugate (Amersham; 100 Wl of 1:50 000 dilution in PBS-T). A col-
ourimetric HRP substrate mix (Turbo TMB, Pierce Biochemicals;
100 Wl) was then added to the ELISA plate wells and the colour
allowed to develop for 35 min before the addition of the stop reagent
(4 M sulphuric acid). ELISA plates were then read at 695 nm.
3. Results
3.1. Immunogenicity of HST analogues
If HST analogues are to be useful as drugs, then the foreign
peptide contained within the molecule should be neither im-
munogenic, nor alter the antigenicity of the HST carrier mol-
ecule. The ideal experiment to test this would be to immunise
human subjects with the analogue, and examine whether an
immune response is elicited. For this sort of study, it is not
possible to use human subjects, so rabbits were deemed a
suitable alternative experimental model. Although human
transferrin is antigenic in rabbits, there is a high degree of
sequence and predicted secondary structure homology be-
tween rabbit transferrin and HST (see [3]). Therefore, a rabbit
immunisation study would demonstrate whether or not the
HIV-1 peptide cleavage site sequence in the context of an
HST analogue is strongly immunogenic or not.
Experimentally, rabbits were immunised with the recombi-
nant M289 analogue protein, and control animals immunised
with either the HIV-1 protease cleavage site peptide, or a
chemical conjugate of the peptide and recombinant w.t.
HST. The amounts of antibody speci¢c for the HIV-1 pro-
tease cleavage site peptide produced by these animals were
determined using a standard antibody capture assay with anti-
gen-coated plates.
Strong immune responses were elicited against the HIV-1
protease cleavage site peptide in all animals immunised with
either the peptide or the HST/peptide conjugate (Fig. 1).
However, the M289 analogue induced only a very poor im-
mune response, barely measurable above background levels.
It could be argued that failure of the foreign peptide in the
M289 analogue to elicit an immune response could be an
Fig. 1. The HIV-1 protease cleavage site in the M289 analogue is
not immunogenic in rabbits. Rabbits were immunised three times
with the M289 analogue, a conjugate of the recombinant wild-type
HST and HIV-1 protease cleavage site peptide, or the peptide alone.
The amounts of antibody speci¢c for the HIV-1 protease cleavage
site were assayed using an antibody capture ELISA. Pre-immune se-
rum was analysed as a control. Immune serum samples were ana-
lysed in triplicate. The results shown here are the mean ELISA re-
sults (absorbance at 695 nm) for all rabbits immunised with a
particular antigen. For pre-immune serum, the value plotted is the
mean of single ELISA readings of serum from each rabbit. Error
bars indicate one standard deviation of the mean.
Fig. 2. Determination of HST speci¢c antibodies. The same samples
as described in Fig. 1 were used to determine the amounts of anti-
body speci¢c for HST. Pre-immune serum was analysed as a con-
trol. Immune serum samples were analysed in triplicate. The results
shown here are the mean ELISA results (absorbance at 695 nm) for
all rabbits immunised with a particular antigen. For pre-immune se-
rum, the value plotted is the mean of single ELISA readings of se-
rum from each rabbit. Error bars indicate one standard deviation of
the mean.
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experimental artefact caused by an inadequate immunisation
procedure, or some unknown immunological inhibitor present
in the protein preparation. One way to show that an immune
response was mounted in these animals would be to demon-
strate the presence of antibodies reactive against the HST
region of the M289 analogue. The M289 analogue should
induce an equivalent titre of anti-HST antibody as the rabbits
immunised with the chemical conjugate. The results of this
experiment are shown in Fig. 2. Animals immunised with
either M289 or the peptide/HST conjugate produced equiva-
lent high titres of anti-HST antibodies. No anti-HST antibod-
ies were detected in serum from animals immunised with the
peptide alone. This shows that the rabbits were correctly im-
munised and were capable of a productive immune response.
4. Discussion
Recently, we proposed a novel approach for the biological
delivery of peptide drugs could be to incorporate the sequence
of the peptide into the structure of a natural transport protein
such as HST [3]. We demonstrated that this was indeed pos-
sible, by inserting a sequence cleaved by HIV-1 protease into a
surface exposed loop of HST. One concern raised over these
HST analogues was the possibility that the HST could en-
hance the immunoreactivity of the peptide, in the same way
that carrier proteins can be used to generate highly immuno-
genic peptide hapten conjugates. In this study, we conducted
rabbit immunisation studies to determine the immunogenicity
of the peptide moiety.
Our studies demonstrate strong immune responses were eli-
cited against the HIV-1 protease cleavage site peptide in all
animals immunised with either the peptide or the HST/peptide
conjugate. However, the M289 analogue induced only a very
poor immune response, barely measurable above background
levels. It could be argued that failure to produce an immune
response against the foreign peptide in the M289 is because
the immune response triggered by HST itself could mask the
antigenicity of the peptide sequence. However, data from two
other studies demonstrate that it is possible to produce strong
immune responses to peptide antigens engineered into very
immunogenic carrier proteins. In the ¢rst, which examined
the immunogenicity of foreign peptides engineered into polio-
virus antigen chimeras [6], de¢ned regions of the CDR2-like
region of the T cell antigen CD4 were inserted into the anti-
genic site 1 of Sabin type 1 poliovirus. Serum from rabbits
immunised with the recombinant virus was strongly immuno-
reactive against both poliovirus, the T cell antigen and soluble
CD4. This was also the case in a second study, which looked
at the immunogenicity of an HIV-1 neutralising epitope in-
troduced into a surface exposed region of the highly immuno-
genic cholera toxin B subunit [7].
In the absence of any further data, it would be unwise to
speculate upon a possible mechanism for the immunogenic
attenuation observed in this study. It is known that there
are di¡erences in processing and presentation of peptides,
peptide-transferrin conjugates and recombinant proteins by
cells of the immune system (see [8^12]), but clearly this re-
quires further investigation. This study is an extension of ear-
lier work to develop alternative means for delivery of peptide
drugs [3,5,13^16]. The new data provided here will be bene¢-
cial not only for our future goals, but could also have an
important impact on the future design of peptide delivery
systems.
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